Sébastien Simoncelli

Imagine pitching your company without any slides.
Just story, relevance, clarity.
Could you do it?

#pitchpractice
#foundermindset
#biotechclarity

You don’t need more likes.
You need more people DMing you saying: “That post made me think.”
Optimise for impact, not applause.

#contentstrategy
#biotechfounders
#socialselling

Founders who wait for 'traction' to start posting will miss the people who could’ve helped build it.
Visibility is a growth lever.

#lifesciencemarketing
#earlystagebiotech
#foundertips

Biotech isn’t boring.
But the way most founders explain it is.
If your post wouldn’t make a curious 16-year-old stop scrolling, try again.

#biotechedge
#founderbranding
#communicationskill

Your target audience doesn’t care about your PhD.
They care if you can solve their $10M problem.
Talk to their priorities, not your credentials.

#lifesciencebiz
#founderinsight
#biotechgrowth

If your drug delivery platform is groundbreaking, why is your content invisible?
Start by answering what only your tech can answer.

#drugdelivery
#biotechfounders
#lifesciencestrategy

Why do most 'innovative' biotech pitches still look like they were written for a 2004 VC deck? Innovation starts with how you tell the story.

#biotechmarketing
#founderbranding
#lifescience

Biotech founders avoid talking about failure.
But your next partner might be more interested in your last mistake than your last milestone.
What did you learn the hard way?

#biotech
#lifesciencefounder
#sciencetalk

Most founders ghost their audience between funding rounds.
Then wonder why their next announcement gets ignored.
In science, consistency builds credibility. Why forget that online?

#StartupVisibility
#FounderMarketing
#LifeScienceGrowth

Link:

[7/7]
The future of reproductive biotech is being shaped right now, in startup labs, not policy rooms.
If you're in life sciences, don’t just follow the hype.
Lead with insight.

Curious how to make ethical science market-ready?

#Genomics #FounderEthics #BiotechNews

[6/7]
Checklist for founders building in this space:
🔲 Validate AI models across diverse ancestries
🔲 Be clear about predictive vs deterministic results
🔲 Partner with ethicists early
🔲 Prioritise regulatory foresight (not just compliance)
🔲 Avoid wellness-washing complex science

[5/7]
Why does this matter for life science founders?

Because this is a collision between:
• Genomics
• Consumer tech
• Ethical biotech

You’re not just building products.
You’re shaping beliefs about what should be possible and what shouldn’t.
The line between care and control is thin.

[4/7]
What are patients being promised?

✅ Reports on risks for heart disease, breast cancer, Alzheimer’s
✅ Trait insights like height or cognitive risk
✅ Options to select embryos with lower lifetime disease burden

🧠 That means: pressure to choose “healthier” babies, and no clear long-term data.

[3/7]
This isn’t just gene editing. It’s gene selection.
Orchid’s model estimates the likelihood of complex diseases based on a polygenic score using machine learning trained on population-level genetic data.

⚠️ But here’s the twist: accuracy depends on ancestry.
White embryos = best data match.

[2/7]
Meet Noor Siddiqui.
Stanford-trained, YC alum, and founder of Orchid.
Her company’s screening tech analyses DNA from just 5 cells of a human embryo.

What does it look for?
Polygenic risk for over 1,200 traits, from schizophrenia to Type 2 diabetes.
It’s already in U.S. fertility clinics.

[1/7]
🚨 Startups are now offering full-genome screening of embryos.

It’s not science fiction. It’s a new reality in IVF, and it’s backed by serious money.

But when tech moves faster than ethics, founders in life sciences need to pause and ask hard questions.

Here’s what’s happening 👇

LinkedIn is full of scientists trying to write like marketers.
What if founders did the opposite?
What would it look like if marketers started writing like scientists?

#SciComm
#LifeScienceBranding
#ContentStrategy

Scientists unlock potential of cytokine adjuvants in mRNA vaccines In the quest to design vaccines that better help the body's immune system fight disease, scientists are always looking for more tools for their arsenal.

Link:

5/5

"To improve is to change; to be perfect is to change often."
– Winston Churchill

Could cytokine mRNA be the future of immunotherapy?
Curious to hear your thoughts 👇

#Immunotherapy #mRNAvaccines #Cytokines

4/5

Why does it matter?
Because we may no longer need bulky adjuvant formulations.
The adjuvant is the code, co-delivered with the antigen, tuned for the desired immune effect.
Less complexity. More precision.

3/5

IL-12, IL-15, GM-CSF.

When added to mRNA vaccine platforms, these cytokines dramatically boosted:
• T cell responses
• Antigen presentation
• Tumour control in mice

All without added toxicity.

2/5

Cytokines aren’t new.
They’re immune messengers, shaping how the body reacts to threats.
But now, researchers are using cytokine-encoding mRNA as adjuvants, turning vaccines into mini-immune training camps.

1/5

mRNA vaccines changed the game.
But what if we could push them further, stronger immunity, lower doses, faster response?
The secret may lie in cytokines.
And scientists just found a way to harness them. 🧵

Why are so many biotech websites still unreadable on mobile?
You raised $30M, but your About page still says 'leveraging synergies' and takes 12 seconds to load.
Who’s responsible for fixing this?

#BiotechMarketing
#UXfail
#FoundersView

CRISPR-mediated DNA methylation editing regulates inflammation and tumor growth Genes, fragments of DNA located on our chromosomes, control much of what happens in cells.

Link:

7/7
"Not everything that counts can be counted, and not everything that can be counted counts."
– Albert Einstein

What’s your take?
Edit the code or just the instructions?

#CRISPR #Epigenetics #CancerResearch

6/7

This kind of tech could unlock safer immunotherapies, inflammation control, or even age-related disease interventions.
Not just what’s in the genome, but how it behaves.
And that opens a whole new chapter.

5/7

It’s also a shift in mindset.
We’ve been focused on editing DNA like a manuscript.
But what if the future is about editing the margins? The formatting? The footnotes?
Same genes. Different expression.

4/7

They targeted a specific methylation site (IFNGR2) linked to inflammatory signalling.

The results?
• Less cytokine storm
• Lower tumour burden
• No off-target chaos

This is precision epigenetics in action.